Background: The recent studies concerning antiviral therapy in HBV-related cirrhosis showed the promising results. This study is aimed at assessing efficacy of lamivudine in patients with HBV-related cirrhosis.
Patients and methods: 41 patients with HBsAg positive-cirrhosis and evidence of viral replication were enrolled in the study. Lamivudine is given 100 mg per day and the follow-up is 12 months.
Results: The rates of HBV DNA undetectable was 58.53%, 68.29% and 87.80% after 36.6 and 12 months, respectively. The rate of HBeAg loss and HBeAg seroconversion are 57.14% and 35.71%. Child-Pugh scores decreased significantly after 6 and 12 months. The complications of cirrhosis were infrequent.
Conclusion: Lamivudine appeared effective and safe in HBV-related hepatic cirrhosis.
